Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors
Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.
Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.
There has been great progress in treating advanced melanoma, states Schadendorf. Checkpoint blockade has made contributions, giving long duration of responses and a median overall survivial of 3 years.
Related Videos
Related Content
